We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$49.3M
Cap. Flow
+$2.89M
Cap. Flow %
0.9%
Top 10 Hldgs %
66.2%
Holding
60
New
23
Increased
11
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$16.9M
2
IVA
Inventiva
IVA
+$9.13M
3
ELVN icon
Enliven Therapeutics
ELVN
+$6.79M
4
FBRX icon
Forte Biosciences
FBRX
+$5.34M
5
ADAG
Adagene
ADAG
+$4.7M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$19.8M
2
ABVX
Abivax
ABVX
+$14.5M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.99M
4
RLMD icon
Relmada Therapeutics
RLMD
+$7.86M
5
ANL
Adlai Nortye
ANL
+$6.09M

Sector Composition

Rank Sector Weight
1 Healthcare 90.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
51
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-315,000
Closed -$6.34M
KALV
52
DELISTED
KalVista Pharmaceuticals
KALV
– –
-985,100
Closed -$19.8M
KPTI icon
53
PUT
Karyopharm Therapeutics
KPTI
$45.8M
– –
-750,000
Closed -$4.18M
NKTR icon
54
Nektar Therapeutics
NKTR
$2.47B
– –
-125,000
Closed -$8.99M
RLAY icon
55
CALL
Relay Therapeutics
RLAY
$4.35B
– –
-150,000
Closed -$1.49M
TXMD icon
56
TherapeuticsMD
TXMD
$24M
– –
-420,421
Closed -$849K
TRAW icon
57
Traws Pharma
TRAW
$8.7M
– –
-511,714
Closed -$936K
EPRX
58
Eupraxia Pharmaceuticals
EPRX
$439M
– –
-680,000
Closed -$4.92M
NEUP
59
Neuphoria Therapeutics
NEUP
$20.9M
– –
-76,728
Closed -$312K
SPRB
60
Spruce Biosciences
SPRB
$151M
– –
-12,200
Closed -$797K
1 2
3

Similar funds

BCP
Bayberry Capital Partners New York $323M AUM 27.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
GWM
Graybill Wealth Management Elmhurst, Illinois $328M AUM 21.42% 1-Year Est. Return
KC
KHIS Custodian Dallas, Texas $316M AUM
HNH
Hopwood Nicholas Hunter $315M AUM

Squadron Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Squadron Capital Management held 60 positions worth $322M, up 18% from $273M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Squadron Capital Management's Q2 2026 filing shows 23 new, 11 increased, 7 reduced and 17 closed positions. Its largest new stake was Enliven Therapeutics: 160,000 shares worth $8.12M. The largest sale was KalVista Pharmaceuticals, an estimated $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

  • Squadron Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 160,000 shares worth $8.12M.
  • Squadron Capital Management added most to C4 Therapeutics in Q2 2026, an estimated $16.9M increase.
  • Squadron Capital Management's biggest Q2 2026 reduction was Relmada Therapeutics, cutting an estimated $7.86M.
  • Squadron Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Squadron Capital Management's ten largest holdings make up 66% of its $322M portfolio in Q2 2026.
  • Squadron Capital Management opened 23 new positions and closed 17 in Q2 2026.
  • Squadron Capital Management's portfolio value rose 18% quarter-over-quarter to $322M.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.